Q3 2026 results · 13 October 2026

J&J's Tremfya sold $2.4bn, up 68%, as Stelara sales more than halved.

$2.4Bsales of Tremfya, up 68%

$4.2Bsales of Darzalex, J&J's top drug

$210Mnet earnings, after a talc charge

Source

Get a note when Johnson & Johnson reports next.

Whatco sends a short notification with the number that matters, and the full story of the company is a tap away.